Eldelumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Eldelumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CXCL10/IP-10
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6502H10024N1736O2026S48
Molar mass 146.5 kg/mol

Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][3] designed for the treatment of Crohn's disease and ulcerative colitis.[4]

This drug was developed by Bristol-Myers Squibb and Medarex[5]

References[edit]

  1. ^ Sandborn, William J.; Colombel, Jean-Frédéric; Ghosh, Subrata; Sands, Bruce E.; Dryden, Gerald; Hébuterne, Xavier; Leong, Rupert W.; Bressler, Brian; Ullman, Thomas (2016-04-01). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's and Colitis. 10 (4): 418–428. ISSN 1873-9946. PMC 4946756Freely accessible. PMID 26721935. doi:10.1093/ecco-jcc/jjv224. 
  2. ^ a b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24. 
  3. ^ Sandborn, William J.; Colombel, Jean-Frédéric; Ghosh, Subrata; Sands, Bruce E.; Dryden, Gerald; Hébuterne, Xavier; Leong, Rupert W.; Bressler, Brian; Ullman, Thomas (2016-04-01). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–428. ISSN 1876-4479. PMC 4946756Freely accessible. PMID 26721935. doi:10.1093/ecco-jcc/jjv224. 
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
  5. ^ "Eldelumab - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24.